

CLAIMS

1. An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof,

5 for use by nasal administration.

2. An aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, for use by nasal administration in antithrombotic treatment.

10

3. The use of an aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, in the manufacture of a medicament for use by nasal administration in antithrombotic treatment.

15

4. The use of an aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof, in the manufacture of a medicament for use by nasal administration in treating thromboembolism.

20

5. A method of treating a patient in need of antithrombotic treatment by nasally administering an aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof.

25

6. A method of treating thromboembolism in a patient in need of such treatment by nasally administering an aqueous pharmaceutical formulation comprising the thrombin inhibitor HOOC-CH₂-(R)-Cgl-Aze-Pab (melagatran), or a pharmaceutically-acceptable derivative thereof.

30